Racecadotril

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Racecadotril is an anti-secretory enkephalinase inhibitor useful in the treatment of diarrhea.

Generic Name
Racecadotril
DrugBank Accession Number
DB11696
Background

Racecadotril has been investigated for the basic science and treatment of Diarrhea, Acute Diarrhea, and Acute Gastroenteritis.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 385.48
Monoisotopic: 385.134779399
Chemical Formula
C21H23NO4S
Synonyms
  • Racecadotril
  • Racecadotrilo

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofAcute diarrhoea•••••••••••••••••••• ••••••• ••••••• •••• ••••••
Symptomatic treatment ofDiarrhea•••••••••••••••••••
Used as adjunct for symptomatic treatment ofDiarrhea••• •••••••••••• •••••••••••••• ••••••• ••••••• ••• ••••••••
Symptomatic treatment ofDiarrhea••••••••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Categories

ATC Codes
A07XA04 — Racecadotril
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as n-acyl-alpha amino acids and derivatives. These are compounds containing an alpha amino acid (or a derivative thereof) which bears an acyl group at its terminal nitrogen atom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
N-acyl-alpha amino acids and derivatives
Alternative Parents
Alpha amino acid esters / Benzyloxycarbonyls / Thioesters / Carboxylic acid esters / Carbothioic S-esters / Sulfenyl compounds / Propargyl-type 1,3-dipolar organic compounds / Monocarboxylic acids and derivatives / Carboximidic acids / Organopnictogen compounds
show 4 more
Substituents
Alpha-amino acid ester / Aromatic homomonocyclic compound / Benzenoid / Benzyloxycarbonyl / Carbonyl group / Carbothioic s-ester / Carboximidic acid / Carboximidic acid derivative / Carboxylic acid ester / Hydrocarbon derivative
show 15 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
76K53XP4TO
CAS number
81110-73-8
InChI Key
ODUOJXZPIYUATO-UHFFFAOYSA-N
InChI
InChI=1S/C21H23NO4S/c1-16(23)27-15-19(12-17-8-4-2-5-9-17)21(25)22-13-20(24)26-14-18-10-6-3-7-11-18/h2-11,19H,12-15H2,1H3,(H,22,25)
IUPAC Name
benzyl 2-{2-[(acetylsulfanyl)methyl]-3-phenylpropanamido}acetate
SMILES
CC(=O)SCC(CC1=CC=CC=C1)C(=O)NCC(=O)OCC1=CC=CC=C1

References

General References
  1. EMC Summary of Product Characteristics: Hidrasec (racecadotril) granules for oral suspension [Link]
PubChem Compound
107751
PubChem Substance
347828061
ChemSpider
96913
RxNav
16738
ChEBI
91508
ChEMBL
CHEMBL2103772
Wikipedia
Racecadotril

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentAcute Diarrhea / Acute Gastroenteritis1
3CompletedTreatmentDiarrhea2
3CompletedTreatmentInfantile Diarrhea1
1CompletedNot AvailableHealthy Male Volunteers1
1CompletedBasic ScienceAntidiarrheals1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Powder, for suspensionOral10 mg
Powder, for suspensionOral30 mg
CapsuleOral
CapsuleOral100.00 mg
Granule, for suspensionOral
PowderOral30 mg
Powder, for suspensionOral6 mg
Granule, for suspensionOral30.00 mg
Granule, for suspensionOral10.00 mg
Powder, for solutionOral10 mg
Capsule, coatedOral100 mg
GranuleOral30 mg
Tablet, orally disintegratingOral10 mg
Tablet, orally disintegratingOral30 mg
TabletOral10 mg
TabletOral30 mg
GranuleOral10 mg
SuspensionOral4 MG/ML
Tablet, film coated
Tablet, film coated175 MG
CapsuleOral100 mg
PowderOral6 mg/1sachet
PowderOral30 mg/1sachet
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00176 mg/mLALOGPS
logP2.72ALOGPS
logP3.17Chemaxon
logS-5.3ALOGPS
pKa (Strongest Acidic)12.6Chemaxon
pKa (Strongest Basic)-2.1Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area72.47 Å2Chemaxon
Rotatable Bond Count11Chemaxon
Refractivity106 m3·mol-1Chemaxon
Polarizability40.84 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSsplash10-014l-1295000000-b84f3c2b1498077b2476
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSsplash10-014l-1395000000-c4e257557748aee5583a
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014l-1295000000-b84f3c2b1498077b2476
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014l-1395000000-c4e257557748aee5583a
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-7693000000-a528b12897c59dcdf060
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-000x-3198000000-3bc170b219d1ae80f57e
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0f6x-3491000000-4f2bd6f237a1310c8d59
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-00di-9010000000-5a4e2001b20e10a6c7d0
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-00kf-6900000000-4614e21f3bbd76a16c05
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-00di-9430000000-8376599269ecd3ff668f
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-181.2277
predicted
DeepCCS 1.0 (2019)
[M+H]+183.58571
predicted
DeepCCS 1.0 (2019)
[M+Na]+190.50319
predicted
DeepCCS 1.0 (2019)

Drug created at October 20, 2016 20:40 / Updated at May 07, 2021 21:07